Company Focus
Sanofi
Latest Sanofi News
Pharmaceutical
US RNA interference (RNAi) specialist Arrowhead Pharmaceuticals today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France’s Sanofi to develop and commercialize four of Arrowhead’s investigational cardiometabolic candidates in Greater China. 2 August 2025
Related News
Insights
Company Spotlight
A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.
Latest News & Features of interest to Sanofi
Generics
Russia is currently experiencing a strong increase in the sales of drugs against alcoholism, as the number of citizens, who suffer from alcohol addiction has significantly increased since 2022, reports The Pharma Letter’s local correspondent. 29 July 2025
Pharmaceutical
Family-owned Boehringer Ingelheim, now Germany’s largest drugmaker by revenue, has reported positive growth in the first half of 2025, with group net sales growing by 6.3% to 14.0 billion euros ($14.7 billion). 29 July 2025
Pharmaceutical
California’s MapLight Therapeutics has announced an oversubscribed $372.5 million Series D financing. 29 July 2025
Pharmaceutical
AstraZeneca posted a robust second-quarter 2025 performance, lifted by record growth in its US business and solid momentum across its key therapy areas.
The UK pharma major reported revenue of $14.5 billion for the three months to June 30, up 12% from a year earlier and ahead of analysts’ forecasts. Pre-tax profit climbed 30% to $3.1 billion, while earnings per share rose 27% to $1.58. 29 July 2025
Biotechnology
The US Food & Drug Administration (FDA) has approved Danish biotech Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD), a rare disorder resulting from decreased or total loss of growth hormone production. 29 July 2025
Pharmaceutical
Shares in CervoMed were up 6% Monday lunchtime after the US company announced positive 32-week data from the extension phase of the Phase IIb RewinD-LB trial showing that oral neflamapimod continues to slow disease progression and demonstrate an effect on a plasma marker of neurodegeneration in dementia with Lewy bodies (DLB). 28 July 2025
Pharmaceutical
US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced positive trial data for its lead candidate gedatolisib. 28 July 2025
Pharmaceutical
Hong Kong-based biotech Neuco United and Shanghai Fosun Pharmaceutica have signed an exclusive licensing agreement for the manufacturing and commercialization of AR1001 in Greater China, encompassing the Chinese mainland, Hong Kong and Macau. 28 July 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved US biotech Biogen’s Qalsody (tofersen) to treat adults with amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 (an enzyme called superoxide dismutase 1) gene – a rare, inherited form of motor neurone disease (MND). 28 July 2025
Pharmaceutical
World Hepatitis Day, marked each year on July 28, is shining a light on what GlobalData calls an “urgent need” for a renewed push to tackle viral hepatitis as mortality rises worldwide. The disease remains among the deadliest infectious threats, affecting more than 300 million people globally. 28 July 2025
Latest In Brief for Sanofi
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Relevant Ones To Watch News
Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker Lundbeck and Japan-based Otsuka’s Rexulti for post-traumatic stress disorder. France’s Sanofi announced it is expanding its respiratory vaccines pipeline with an up to $1.6 billion acquisition of UK biotech Vicebio. French biotech Abivax released new Phase III data on its investigational ulcerative colitis candidate obefazimod that saw its shares nearly quadruple. Also of note was the latest setback for Sarepta’s Duchenne muscular dystrophy drug Elevidys, when the European Medicines human health committee, the CHMP, declined partner Roche’s accelerated approval of the drug. 27 July 2025
18 July 2025
30 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze